Javier A Menendez

Summary

Country: Spain

Publications

  1. doi request reprint Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Biochim Biophys Acta 1801:381-91. 2010
  2. pmc Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
  3. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
  4. pmc Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    PLoS ONE 4:e6251. 2009
  5. pmc Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona, ICO Girona
    Oncotarget 3:1600-14. 2012
  6. pmc Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Aging (Albany NY) 4:393-401. 2012
  7. pmc Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
    C Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Spain
    Br J Cancer 106:1406-14. 2012
  8. pmc The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona ICO Girona, Girona, Spain
    Cell Cycle 12:1166-79. 2013
  9. doi request reprint Metformin is synthetically lethal with glucose withdrawal in cancer cells
    Javier A Menendez
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:2782-92. 2012
  10. pmc Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss
    Jose Manuel Fernandez-Real
    Department of Diabetes, Endocrinology and Nutrition, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Instituto de Salud Carlos III, 28029 Madrid, Spain
    Nutr Metab (Lond) 7:14. 2010

Collaborators

Detail Information

Publications87

  1. doi request reprint Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Biochim Biophys Acta 1801:381-91. 2010
    ....
  2. pmc Metformin: multi-faceted protection against cancer
    Sonia del Barco
    Medical Oncology, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 2:896-917. 2011
    ..Current and future clinical trials will elucidate whether metformin has the potential to be used in preventive and treatment settings as an adjuvant to current cancer therapeutics...
  3. pmc Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Oncotarget 3:395-8. 2012
    ....
  4. pmc Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    PLoS ONE 4:e6251. 2009
    ..Therapeutic targeting autophagosome formation/function might represent a novel molecular avenue to reduce the emergence of Tzb resistance in HER2-dependent breast carcinomas...
  5. pmc Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona, ICO Girona
    Oncotarget 3:1600-14. 2012
    ..The degree of predictive accuracy warrants further investigation in the clinical situation...
  6. pmc Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Aging (Albany NY) 4:393-401. 2012
    ..Our current findings provide new insight into how mitochondrial division is integrated into the reprogramming factors-driven transcriptional network that specifies the unique pluripotency of stem cells...
  7. pmc Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
    C Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Spain
    Br J Cancer 106:1406-14. 2012
    ....
  8. pmc The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona ICO Girona, Girona, Spain
    Cell Cycle 12:1166-79. 2013
    ....
  9. doi request reprint Metformin is synthetically lethal with glucose withdrawal in cancer cells
    Javier A Menendez
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:2782-92. 2012
    ....
  10. pmc Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss
    Jose Manuel Fernandez-Real
    Department of Diabetes, Endocrinology and Nutrition, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Instituto de Salud Carlos III, 28029 Madrid, Spain
    Nutr Metab (Lond) 7:14. 2010
    ..We aimed to evaluate circulating HER-2 concentrations in association with insulin resistance in healthy and obese subjects...
  11. pmc Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection
    Gerard Aragones
    Centre de Recerca Biomedica, Hospital Universitari de Sant Joan, Institut d Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
    BMC Gastroenterol 10:92. 2010
    ..The present study aimed to investigate whether serum FASN concentration may provide a direct link between HIV and/or HCV viral infections and lipid metabolic disorders commonly observed in HIV/HCV-infected patients...
  12. pmc Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer
    Javier A Menendez
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Aging (Albany NY) 3:1063-77. 2011
    ....
  13. ncbi request reprint Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Int J Oncol 33:1165-76. 2008
    ....
  14. pmc tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    BMC Cancer 8:377. 2008
    ..We here investigated the anti-HER2 effects of phenolic fractions directly extracted from Extra Virgin Olive Oil (EVOO) in cultured human breast cancer cell lines...
  15. pmc Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    Bruna Corominas-Faja
    Metabolism and Cancer Group Translational Research Laboratory Catalan Institute of Oncology Girona, Catalonia, Spain Girona Biomedical Research Institute IDIBGi Girona, Catalonia, Spain
    Cell Cycle 12:3390-404. 2013
    ..Our findings highlight the benefit of administration of silibinin in combination with EGFR TKIs to target CSCs and minimize the ability of tumor cells to escape cell death in EGFR-mutant NSCLC patients...
  16. pmc Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Girona, Catalonia, Spain
    Rejuvenation Res 15:3-21. 2012
    ....
  17. doi request reprint Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
    Sílvia Cufí
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:1235-46. 2012
    ....
  18. ncbi request reprint Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain Girona Biomedical Research Institute IdIBGi, Girona, Catalonia, Spain
    Food Chem Toxicol 60:360-8. 2013
    ....
  19. doi request reprint Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Invest New Drugs 30:846-52. 2012
    ....
  20. doi request reprint Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology, 2Girona Biomedical Research Institute, Girona, Catalonia, Spain
    Int J Oncol 38:1533-47. 2011
    ..Oleaceae secoiridoids could provide a valuable phytochemical platform for the design of more pharmacologically active second-generation phytopharmaceutical anti-breast cancer molecules with a unique mode of action...
  21. doi request reprint Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, Avenida de Francia s n, Girona, Catalonia, Spain
    Biochem Biophys Res Commun 397:27-33. 2010
    ..Intrinsic genetic plasticity to efficiently drive the emergence of the CD44(pos)/CD24(neg/low) mesenchymal phenotype may account for de novo resistance to HER2 targeting therapies in basal-like BC carrying HER2 gene amplification...
  22. ncbi request reprint Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology ICO, E 17007 Girona, Catalonia, Spain
    Int J Oncol 37:669-78. 2010
    ....
  23. pmc The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer
    Sílvia Cufí
    1 Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona ICO Girona, Girona, Spain 2 Molecular Oncology, Girona Biomedical Research Institute IdIBGi, Girona, Spain 3
    Sci Rep 3:2469. 2013
    ..Adding chloroquine to trastuzumab-based regimens may therefore improve outcomes among women with autophagy-addicted HER2-positive breast cancer...
  24. doi request reprint Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Catalonia, Spain
    J Cell Physiol 226:52-7. 2011
    ..These findings, altogether, may provide crucial insights concerning clinical studies aimed to accurately describe HER2 ECD as a potential predictor of response or resistance to the HER2-targeted drugs trastuzumab and lapatinib...
  25. pmc Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    Cell Cycle 11:4211-21. 2012
    ....
  26. ncbi request reprint Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contra
    Eugeni Lopez-Bonet
    Department of Pathology, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
    Int J Oncol 36:107-15. 2010
    ..These findings warrant forthcoming studies to confirm both the accuracy and the prognostic value of PP-mTOR(Ser2481) as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas...
  27. ncbi request reprint Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Girona, Spain
    Cell Cycle 10:1295-302. 2011
    ....
  28. pmc The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 12:207-18. 2013
    ....
  29. pmc Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs
    Bruna Corominas-Faja
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Aging (Albany NY) 4:480-98. 2012
    ....
  30. pmc Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Drug Resist Updat 14:212-23. 2011
    ....
  31. ncbi request reprint Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on
    Javier A Menendez
    Catalan Institute of Oncology ICO, Girona Biomedical Research Institute IdIBGi, Spain
    Int J Oncol 34:43-51. 2009
    ....
  32. ncbi request reprint mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb)
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Avenida de Francia, S N, ES 17005 Girona, Spain
    Clin Transl Oncol 11:455-9. 2009
    ....
  33. doi request reprint Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line mod
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology Girona, ICO Girona, E 17007 Girona, Catalonia, Spain
    Int J Oncol 39:1455-79. 2011
    ....
  34. doi request reprint Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 407:412-9. 2011
    ..Our current findings may be extremely helpful to design successful combinatorial strategies aimed to circumvent the occurrence of de novo resistance to HER2-directed drugs using survivin antagonists...
  35. pmc Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2459. 2013
    ....
  36. ncbi request reprint Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    Int J Oncol 31:769-76. 2007
    ....
  37. doi request reprint Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncol Rep 27:1887-92. 2012
    ....
  38. ncbi request reprint Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs)
    Alejandro Vazquez-Martin
    Unit of Translational Research, Catalan Institute of Oncology Girona, Girona Biomedical Research Institute, Girona, Spain
    Cell Cycle 10:3140-52. 2011
    ..Nucleolar- and NOR-associated P-Raptor (Ser706) may physically link mTORC1 signaling to ever-growing nucleolus plurifunctionality including ribosome biogenesis, cell stress sensor and cell cycle/aging control...
  39. ncbi request reprint Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology Girona ICO Girona, Girona, Catalonia, Spain
    Cell Cycle 10:1144-51. 2011
    ....
  40. ncbi request reprint The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, Girona, Catalonia, Spain
    Cell Cycle 8:88-96. 2009
    ..The importance of mTOR/p70S6K1-sensed ROS status at mediating the anti-oncogenic effects of metformin might represent a previously unrecognized linkage molecularly connecting its anti-aging and anti-cancer actions...
  41. pmc Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
    Begoña Martin-Castillo
    Unit of Clinical Research, Catalan Institute of Oncology Girona ICO Girona, Catalonia, Spain
    Cell Cycle 12:225-45. 2013
    ..g., luminal/HER2 vs. basal/HER2) would distinctly benefit from trastuzumab-based therapy ab initio...
  42. pmc IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Sci Rep 3:2560. 2013
    ....
  43. pmc Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
    Cristina Oliveras-Ferraros
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:4020-32. 2012
    ..The systematic determination of SLUG/SNAIL2 as a stem/CD44+CD24(-/low) cell-associated protein may improve the therapeutic management of HER2+ breast carcinomas...
  44. ncbi request reprint AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology Health Services Division of Catalonia, Catalonia, Spain
    Cell Cycle 8:3679-83. 2009
    ....
  45. ncbi request reprint Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays
    Javier A Menendez
    Girona Biomedical Research Institute, Medical Oncology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Int J Mol Med 22:433-9. 2008
    ....
  46. doi request reprint The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Girona ICO Girona, Dr Josep Trueta University Hospital, Ctra França s n, 17007, Girona, Catalonia, Spain
    Breast Cancer Res Treat 126:355-64. 2011
    ....
  47. ncbi request reprint Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Health Services Division of Catalonia, Catalonia, Spain
    Int J Oncol 35:1369-76. 2009
    ....
  48. ncbi request reprint An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
    ....
  49. pmc Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
    Sílvia Cufí
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 4:1484-95. 2013
    ....
  50. pmc Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 12:555-78. 2013
    ....
  51. doi request reprint Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
    Cristina Oliveras-Ferraros
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 11:865-70. 2012
    ..Restored antigenicity and immunogenicity of tumor cells may represent a previously unrecognized primary mode of action underlying the cancer-preventive effects of metformin...
  52. doi request reprint Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Cell Cycle 11:2422-6. 2012
    ....
  53. ncbi request reprint Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis
    Sílvia Cufí
    Catalan Institute of Oncology, Girona
    Cell Cycle 9:4461-8. 2010
    ....
  54. ncbi request reprint Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona, Catalonia, Spain
    Cell Cycle 9:3807-14. 2010
    ....
  55. pmc Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Oncotarget 5:2344-8. 2014
    ..Perhaps then, the oncobiguanides, as we call them here, could be viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides. ..
  56. pmc One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin
    Javier A Menendez
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology Girona ICO Girona, Girona, Spain
    Aging (Albany NY) 4:894-8. 2012
    ....
  57. pmc Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
    Alejandro Vazquez-Martin
    Metabolism and Cancer Group, Translational Research Laboratory, Catalan Institute of Oncology, Girona, Spain
    Sci Rep 2:964. 2012
    ....
  58. doi request reprint mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging
    Javier A Menendez
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 10:3658-77. 2011
    ....
  59. ncbi request reprint Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
    Javier A Menendez
    Translational Research Unit, Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Josep Trueta University Hospital of Girona, 17, 007 Girona, Catalonia, Spain
    Nat Rev Cancer 7:763-77. 2007
    ..FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer...
  60. doi request reprint Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells
    Alejandro Vazquez-Martin
    Translational Research Laboratory, Catalan Institute of Oncology ICO, Girona, Spain
    Cell Cycle 11:974-89. 2012
    ..AMPK-activating anti-reprogramming strategies may provide a roadmap for the generation of novel cancer therapies that metabolically target tumor-propagating cells...
  61. doi request reprint AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology, Girona ICO Girona, Hospital de Girona Dr Josep Trueta, Ctra França s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 378:488-93. 2009
    ..FASN release might represent a previously unrecognized mechanism through which AMPK monitor and restores cellular energy state in response to increasing AMP/ATP ratios...
  62. ncbi request reprint The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Oncol Rep 25:135-40. 2011
    ....
  63. pmc Extracellular fatty acid synthase: a possible surrogate biomarker of insulin resistance
    Jose Manuel Fernandez-Real
    Department of Diabetes, Endocrinology and Nutrition, Institutd Investigació Biomédica de Girona, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Girona, Catalonia, Spain
    Diabetes 59:1506-11. 2010
    ..The aim of this study was to determine whether circulating FASN could be a biomarker of overnutrition-induced metabolic stress and insulin resistance in common metabolic disorders...
  64. ncbi request reprint Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling
    Cristina Oliveras-Ferraros
    Metabolism and Cancer Laboratory, Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Catalonia, Spain
    Int J Oncol 32:113-20. 2008
    ..The synergism that we have observed may explain the favorable clinical responses that have been achieved in clinical studies, in which patients are administered PTX first, and then GEM...
  65. doi request reprint The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO Girona, Dr Josep Trueta University Hospital of Girona, Avenida de Francia s n, E 17007 Girona, Catalonia, Spain
    Biochem Biophys Res Commun 380:638-43. 2009
    ..These results reveal for the first time that PP-mTOR(Ser2481) may be unexpectedly involved in the terminal stages of cytokinesis...
  66. doi request reprint Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype
    Sílvia Cufí
    Unit of Translational Research, Catalan Institute of Oncology Girona, Girona, Catalonia, Spain
    Cell Cycle 10:3871-85. 2011
    ..This is the first report demonstrating that autophagy is mechanistically linked to the maintenance of tumor cells expressing high levels of CD44 and low levels of CD24, which are typical of BCSCs...
  67. pmc Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells
    Javier A Menendez
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Spain
    BMC Cancer 7:80. 2007
    ..e., oleic acid) have been recently described, the anti-breast cancer activities of EVOO non-glyceridic constituents--which consist of at least 30 phenolic compounds--remained to be evaluated...
  68. ncbi request reprint Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
    ..Our results establish EGCG as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug...
  69. doi request reprint Her-2/neu-induced "cytokine signature" in breast cancer
    Alejandro Vazquez-Martin
    Fundación Privada de Investigación Biomédica de Girona Dr Joseph Trueta Instituto Catalá de Oncología de Girona, Catalonia, Spain
    Adv Exp Med Biol 617:311-9. 2008
    ....
  70. ncbi request reprint Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer
    Javier A Menendez
    Catalan Institute of Oncology, Girona Biomedical Research Institute, Hospital Universitari de Girona Josep Trueta, Girona, Catalonia, Spain
    Clin Chem 55:425-38. 2009
    ..An emerging paradigm supports the notion that deregulation of fatty acid synthase (FASN)-catalyzed de novo FA biogenesis could play a central role in the pathogenesis of metabolic diseases sharing the hallmark of insulin-resistance...
  71. doi request reprint Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells
    Cristina Oliveras-Ferraros
    Unit of Translational Research, Catalan Institute of Oncology, Girona, Spain
    J Cell Biochem 112:10-29. 2011
    ....
  72. doi request reprint The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO, Girona Biomedical Research Institute IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Catalonia, Spain
    J Cell Biochem 105:1147-52. 2008
    ..Our findings not only confirm a non-oncogenic role for HER2 in the process of adipose differentiation but further suggest that HER2 might represent a previously unrecognized target to manage obesity via the lipogenic enzyme FASN...
  73. ncbi request reprint Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer
    Alejandro Vazquez-Martin
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Avenida de Francia s n, 17007 Girona, Catalonia, Spain
    Eur J Cancer 43:1117-24. 2007
    ....
  74. ncbi request reprint Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9)
    Javier A Menendez
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Girona, Catalonia, Spain
    Curr Pharm Biotechnol 7:495-502. 2006
    ..Only then we will know whether the old "Mediterranean dietary traditions" will become a new molecular approach in the management of cancer disease...
  75. ncbi request reprint Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena
    Begoña Martin-Castillo
    Catalan Institute of Oncology, Girona, Catalonia, Spain
    Cell Cycle 9:1057-64. 2010
    ..Ongoing chemopreventive, neoadjuvant and adjuvant trials should definitely establish whether metformin's ability to kill the "dandelion root" beneath the "cancer soil" likely exceeds metformin-related dangers of hormesis...
  76. ncbi request reprint Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells
    Alejando Vazquez-Martin
    Catalan Institute of Oncology Health Services Division of Catalonia, 17007 Girona, Catalonia, Spain
    Oncol Rep 18:973-80. 2007
    ....
  77. doi request reprint Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states
    Cristina Oliveras-Ferraros
    Catalan Institute of Oncology, Girona, Catalonia, Spain
    Rejuvenation Res 13:519-26. 2010
    ....
  78. ncbi request reprint BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer
    Joan Brunet
    Catalan Institute of Oncology ICO Health Services Division of Catalonia, Catalonia, Spain
    Mol Carcinog 47:157-63. 2008
    ..Alternatively, new forthcoming ACCA inhibitors may be relevant in the management of BRCA1-dependent breast cancer susceptibility and development...
  79. ncbi request reprint Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling
    Eugeni Lopez-Bonet
    Department of Pathology, Dr Josep Trueta University Hospital of Girona, E 17007 Girona, Catalonia, Spain
    Oncol Rep 20:1369-74. 2008
    ..Forthcoming studies should definitely determine if the clinico-pathological features of NEBC indeed represent an independent good-prognosis subgroup of BC gene signature...
  80. ncbi request reprint The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis
    Alejandro Vazquez-Martin
    Catalan Institute of Oncology ICO and Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital, E 17007 Girona, Catalonia, Spain
    Cell Cycle 8:2385-98. 2009
    ....
  81. ncbi request reprint Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells
    Javier A Menendez
    Foundation of the Recerca Bio Medical Institute of Girona Dr Josep Trueta, University Hospital of Girona, Dr Josep Trueta, Girona, Catalonia, Spain
    Curr Opin Clin Nutr Metab Care 9:346-57. 2006
    ..This review documents our rapidly changing perspectives on the function of fatty acid synthase-catalyzed endogenous fatty acid biogenesis in cancer biology...
  82. pmc Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
    Javier A Menendez
    Catalan Institute of Oncology ICO, Health Services Division of Catalonia, Girona Biomedical Research Institute IdIBGi, Medical Oncology, Dr, Josep Trueta, University Hospital of Girona, Catalonia, Spain
    Breast Cancer Res 9:111. 2007
    ....
  83. doi request reprint Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men
    José M Moreno-Navarrete
    Department of Diabetes, CIBERobn Fisiopatología de la Obesidad y Nutrición CB06 03 010, Girona, Spain
    Obesity (Silver Spring) 17:1755-61. 2009
    ..01). In summary, adult white men with the Ile 1483 variant of the FASN gene seem protected from developing central obesity through decreased adipose tissue FASN activity...
  84. doi request reprint Direct antitumour activity of zoledronic acid: preclinical and clinical data
    Joaquim Bosch-Barrera
    Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Clin Transl Oncol 13:148-55. 2011
    ..Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed...
  85. ncbi request reprint Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells
    Cristina Oliveras Ferraros
    Catalan Institute of Oncology ICO and Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital, Girona, Catalonia, Spain
    Cell Cycle 8:1633-6. 2009
    ..These findings further support a tight relationship between the activation status of AMPK and the chromosomal and cytoskeletal checkpoints of cell mitosis at the transcriptional level...
  86. ncbi request reprint Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
    ..Indeed, OA-induced transcriptional repression of HER2 oncogene may represent a novel genomic explanation linking "Mediterranean diet", olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas...